Responses
Poster Abstracts
Abstracts
62
Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial
Compose a Response to This Article
Other responses
No responses have been published for this article.